Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease. It is characterized by relentless development of kidney cysts, hypertension, and eventually end-stage renal disease (ESRD). ADPKD is associated abdominal fullness and pain, cyst hemorrhage, nephrolithiasis, cyst infection, hematuria, and reduced quality of life, among other symptoms. The disease is a consequence of mutations in \textit{PKD1} or \textit{PKD2}, encoding polycystin 1 and polycystin 2, respectively. Many recent advances have been made in understanding and managing ADPKD. This Core Curriculum outlines the different aspects of molecular genetics, pathophysiology, diagnosis, and management of kidney and extrarenal complications in ADPKD.

**Additional Readings**


**Epidemiology**

ADPKD was first described over 300 years ago. Population-based epidemiologic studies with ascertainment of autopsies have estimated that ADPKD affects 1 in 400 to 1000 live births, or 12.5 million people worldwide. Other studies based on clinical registry data suggest lower prevalence rates, ranging from 1 in 543 to 1 in 4000. ADPKD affects both sexes equally, and occurs in all ethnicities. It accounts for 5% to 10% of end-stage renal disease (ESRD) cases, making it the 4th leading global cause for kidney failure. In the United States, incidence rates of ESRD due to ADPKD are higher in men than in women (8.2 compared to 6.8 per million, respectively). In recent years, some studies have reported
later onset of ESRD; this may be due to reduced cardiovascular mortality of older patients before reaching ESRD or increased access of older patients to kidney replacement therapy.

Additional Readings


GENETICS

ADPKD is a Mendelian autosomal dominant disorder, thus individuals at risk have a 50% chance of inheriting the disease. It is genetically heterogeneous, with 2 causative genes identified: PKD1, which encodes polycystin 1 (PC-1) and accounts for 85% of cases; and PKD2, which encodes polycystin 2 (PC-2) and accounts for 15% of cases (Figure 1). Population-based studies from Canada and United States have suggested a higher prevalence of PKD2-associated disease, such that mutations in this gene may account for up to one fourth to one third of all ADPKD cases. While some have postulated that there is a third PKD gene, convincing evidence to support this putative gene is lacking.

ADPKD has a strikingly high phenotypic variability. Mutations in PKD2 versus PKD1 lead to much milder disease, with average ages at ESRD of 79.7 and 58.1 years respectively (Table 1). Milder disease is also noted in ADPKD cases associated with non-truncating vs truncating mutations of PKD1 (the latter account for 65% of PKD1 mutations). The genotype-phenotype relationship in ADPKD is not completely understood. The disease is associated with a variety of phenotypes, from newborn infants with massive cystic kidneys to patients whose kidney function persists at adequate levels well into old age. Key influences determining this variability are the identity of the affected locus (PKD1 vs PKD2 mutation), the allelic variant (truncating, non-truncating, or hypomorphic), timing of gene inactivation, mosaicism, and genetic background. Male patients may have a slightly more severe phenotype. Affected family members may have discordant disease severity, suggesting a role for both genetic and environmental modifiers.

In 10% to 15% of patients with ADPKD, there is no positive family history for the disease. Reasons for such cases include de novo mutations (5% of cases), mild disease from PKD2 mutations and non-truncating PKD1 mutations, mosaicism, or unavailability of parental medical records.
Additional Readings


**PATHOGENESIS**

During the past few years, the understanding ADPKD pathogenesis has advanced substantially; nonetheless, the function of the polycystins and the molecular mechanisms underlying disease development are still poorly understood. The polycystins constitute a subfamily of protein channels and are thought to regulate intracellular calcium signaling. Polycystins are expressed in many tissues, including renal tubular epithelia, hepatic bile ducts, and pancreatic ducts. PC-1 is localized to the primary cilium and to structures involved in cell-cell contacts (eg, tight junctions). PC-1 probably functions as a receptor and/or adhesion molecule, while PC-2, a calcium-permeable non-selective cation channel, is found on the primary cilium, endoplasmic reticulum, and possibly the plasma membrane. These polycystins interact to form the PC complex, which localizes to the primary cilia and plays a role in intracellular calcium regulation.

Cystogenesis in ADPKD is not fully understood, although several hypotheses have been evolving. The somatic second-hit mutation model suggests that cystogenesis starts after a somatic mutation occurs in the unaffected allele, increasing the functional loss of the causative gene from 50% to 100%. In other words, ADPKD is considered recessive at the cellular level. This model is based on multiple observations, including the focal nature of cystogenesis (ie, less than half of renal epithelial tubular cells become cystic, even though the inherited genetic mutation is present in all cells). Additionally, it has been observed that the normal allele of the affected ADPKD gene in cystic cells undergoes loss or mutation. Recent evidence suggests that for cystogenesis to occur, a complete loss of function is not required; rather, functional PC-1 or PC-2 must be reduced to a certain threshold level. Below this critical threshold, PC-1 dosage correlates with disease severity in relation to both rate of cyst initiation and progression.

Mutations in *PKD1* or *PKD2* lead to a reduction in intracellular calcium, an increase in cyclic adenosine monophosphate (cAMP), activation of protein kinase A, and an increase in sensitivity of collecting duct principal cells to the constant tonic effect of vasopressin (Figure 2). The disruption in calcium signaling coupled with enhanced cAMP signaling activate downstream signaling pathways responsible for impaired tubulogenesis, cell proliferation, increased fluid secretion, and interstitial inflammation. Abnormal epithelial chloride secretion occurs through the cAMP-dependent transporter encoded by the *CFTR* gene and plays an important role in generating and maintaining fluid-filled cysts in ADPKD. Other pathogenic pathways may include activation of mTOR, Wnt, or hedgehog signaling; direct effects of PC-1 fragments on gene transcription; and increased aerobic glycolysis.
**KIDNEY PATHOLOGY**

Kidneys in patients with ADPKD are characterized by cysts that gradually form and grow in number and size. In early disease, the kidney contains few fluid-filled cysts and a large amount of well-preserved parenchyma. The cysts originate from the epithelia of only 1-5% of nephrons and are bordered by a single layer of tubular cells that proliferate more rapidly and are less differentiated than normal. Cysts arise mostly from the distal nephron and collecting duct; they detach as they expand in volume. The cystic epithelium secretes large amounts of chemokines and cytokines, which likely induce an inflammatory response surrounding the cysts. In advanced ADPKD, marked enlargement of the kidneys, vascular remodeling, and interstitial fibrosis are present (Figure 3). Benign adenomas are noted in 25% of kidneys of patients affected by ADPKD.

**Additional Readings**


**DIAGNOSIS**

**Imaging**

The diagnosis of ADPKD relies primarily on imaging, although some cases are diagnosed by genetic testing. Typical imaging findings from patients with ADPKD reveal large kidneys with multiple bilateral cysts (Figure 4). Factors important in diagnosing the disease include family history of ADPKD, age of patient, and number of kidney cysts. Given its availability,
safety, and low cost, ultrasonography is the imaging modality of choice for pre-symptomatic diagnosis. Age-dependent ultrasound criteria for both diagnosis and disease exclusion have been established for patients with positive family history (see Table 2). Specifically, the presence of a total of three or more kidney cysts for at-risk individuals aged 15-39 years and two or more cysts in each kidney for at-risk individuals aged 40-59 years are sufficient for a diagnosis of ADPKD. If ultrasonography results are equivocal, magnetic resonance imaging (MRI) or computed tomography (CT) may clarify the diagnosis. Excluding the disease in at-risk individuals also depends on their age, which in turn dictates the imaging modality. For individuals older than 40 years, absence of kidney cysts on ultrasound excludes ADPKD; in younger individuals (<40 years), MRI is superior to ultrasound for excluding ADPKD. A recent study of 73 affected and 82 non-affected individuals suggested that finding less than 5 cysts by MRI is sufficient to exclude the diagnosis of ADPKD in potential living related kidney donors. A contrast-enhanced CT scan with thin slices likely provides similar information, but this has not been ascertained in formal studies.

In the absence of a family history, these imaging-based criteria do not apply. In such situations, multiple factors should be considered, including the age of the patient, the presence of associated manifestations (eg, liver cysts), and findings or family history suggestive of other genetic disorders. ADPKD is the most likely diagnosis in the presence of bilaterally enlarged kidneys and innumerable (>10) cysts in each kidney. Of note, other genetic diseases (eg, tuberous sclerosis, von Hippel-Lindau disease, and autosomal dominant tubulointerstitial kidney disease) can be associated with kidney cysts. When suggestive findings are noted, the differential diagnosis should be broadened (summarized in Table 3).

A practical algorithm for diagnostic evaluation of patients 18 years or older with kidney cysts is shown in Figure 5.

**Additional Reading**


**Genetic Testing**

Genetic testing is not always required for diagnosis but may be helpful when imaging results are uncertain and/or a firm diagnosis is required, as in identifying living-related kidney donors or in atypical cases (eg, early and severe PKD, kidney failure without significant enlargement of the kidneys, marked discordant disease within family, marked asymmetry in disease severity between kidneys, or very mild PKD). Genetic testing is also useful in diagnosis of sporadic PKD with no family history or PKD with syndromic features. Such testing can be helpful in reproductive counseling as well. When effective disease modifying therapies become available, it will be beneficial to test young patients to confirm the diagnosis prior to starting treatment.

Currently, the most common method used for molecular diagnosis of ADPKD is direct mutation screening by Sanger sequencing of the *PKD1* and *PKD2* genes. This can be followed by multiplex-dependent probe amplification (MLPA) in cases with negative DNA sequencing results. Next-generation sequencing technologies have a potential for high-
throughput screening and lower cost. Currently, molecular screening is available commercially but remains expensive and often difficult to interpret. More than 1270 and 200 pathogenic mutations have been reported for \textit{PKD1} and \textit{PKD2}, respectively (http://pkdb.mayo.edu). Up to 15\% of patients with suspected ADPKD do not have a mutation in these genes, despite a comprehensive screen.

**Additional Readings**


**Pre-symptomatic Screening of Patients at Risk for ADPKD**

Pre-symptomatic screening of ADPKD is not currently recommended for at-risk children. A positive diagnosis might have future implications on a child's career, insurability, and education. A positive diagnosis could cause an emotional burden as well. Prior to testing a child, clinicians should have a discussion with the parents or guardian. Nevertheless, at-risk children should be monitored for early presentations of the disease that require treatment (eg, hypertension). Pre-symptomatic screening of adults at risk for ADPKD is typically performed by ultrasonography, but MRI can be considered.

**CLINICAL MANIFESTATIONS AND MANAGEMENT**

**Kidney Manifestations**

ADPKD can present with hypertension, pain, hematuria, proteinuria, or decreased glomerular filtration rate (GFR). The age of onset of these manifestations is variable. The clinical manifestations of patients with \textit{PKD1} or \textit{PKD2} mutations are fully overlapping, but the former is associated with larger kidneys, more severe disease, and younger age at ESRD incidence. The different kidney manifestations in ADPKD are summarized in the first section of Table 4.

**Cyst Growth and Disease Monitoring**—As noted, ADPKD is characterized by gradual formation and enlargement of bilateral kidney cysts during the lifetime of the patient. Until age 40 to 60 years, kidney function may remain within the normal range, making GFR ascertainment less useful in monitoring the disease in its early stages. At the point that GFR decline has started, physical changes in the kidneys are visible on imaging studies: they become notably enlarged with little recognizable parenchyma. At this stage, the average rate of GFR decline is 4.4-5.9 ml/min per year.

Total kidney volume (TKV) is a better tool for monitoring and prognosticating in early stages of ADPKD. TKV, measured by MRI or CT scan, is an accurate estimate of kidney
cyst burden and correlates with multiple kidney manifestations in ADPKD such as pain, hypertension, hematuria, and proteinuria. TKV and cyst volume increase exponentially in all patients with ADPKD but at variable rates (5-6% per year on average). Although patients with PKD1-related disease have larger kidneys and more cysts than those with PKD2 mutations, the rate of growth is not different. However, most regulatory agencies have not yet accepted TKV as a primary endpoint in clinical trials. Once disease-modifying therapies become available, repeat imaging to follow TKV may be indicated in clinical practice.

A classification of ADPKD has been developed based on age and height-adjusted TKV. This classification stratifies patients into different classes (class 1A through 1E), which translate into varying rates of decline in GFR (http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754). This tool is useful in identifying individuals who are at higher risk for disease progression and estimating the age at which the patient will reach ESRD (Figure 6). For instance, comparing subclass 1E to 1A, the frequency of reaching ESRD within 10 years is substantially greater (66.9% vs 2.4%). This classification is useful in clinical trial settings to identify patients with rapid disease progression who might benefit most from therapy, as opposed to patients who progress slowly and might not need therapy. Knowing the patient's classification also may be helpful in the clinical practice setting for counseling and treatment planning.

Additional Readings


Early Manifestations—Impaired urinary concentrating capacity is an early sign of ADPKD. This symptom precedes kidney cyst formation and is present in up to 60% of children with the disease. In cross-sectional studies and prospective studies, respectively, severity of PKD and the rate of disease progression correlate with plasma copeptin levels, a surrogate of vasopressin.

Additional Reading

Hypertension—Hypertension (blood pressure [BP] > 140/90 mm Hg) is the most common manifestation of ADPKD. It occurs in 50-70% of cases prior to any significant decline in kidney function, with an average age of onset of 30 years. Elevated BP may be detected in a small but significant percentage of children with ADPKD. Increased BP in patients with ADPKD has been attributed to several causes including activation of the renin-angiotensin-aldosterone system (RAAS), increase in sympathetic tone, and primary vascular dysfunction. The most essential factor is activation of the intrarenal RAAS possibly caused by the stretching and compression of the vascular tree by cyst expansion, leading to ischemia. RAAS activation has a potential mitogenic effect on kidney cysts, supported by studies in animals. The HALT-PKD study is a recent randomized, double-blind, placebo-controlled clinical trial that examined the role of RAAS blockade in patients with early and advanced stages of ADPKD. Monotherapy with angiotensin-converting enzyme (ACE) inhibitors was found to be associated with good BP control in the majority of patients. In patients with early (15 to 49 years of age; GFR > 60 ml/min) vs later stage ADPKD, rigorous blood pressure control (BP target range, 95-110/60-75 mm Hg) was associated with slower increase in TKV; more rapid decline in estimated GFR (eGFR) during the first 4 months of treatment, with a slower decline thereafter (an overall eGFR effect was absent); a smaller increase in renal vascular resistance; and a greater decline in left ventricular mass index. Dual RAAS blockade with lisinopril and telmisartan had no beneficial effect compared to lisinopril alone in these patients or in patients with more advanced ADPKD (18 to 64 year of age; GFR between 25 and 60 ml/min).

In patients with ADPKD, hypertension is associated with progression to ESRD and cardiovascular morbidity and mortality. The diagnosis of hypertension is often made late. Children with ADPKD with high or borderline high BP have been found to have attenuated nocturnal dipping, exaggerated blood pressure response to exercise, and higher left ventricular mass indices. This suggests that target organ damage develops early in ADPKD. Early detection and treatment of hypertension particularly in children and young adults is indicated. Screening of children with family history of ADPKD from age 5 years onward, with rescreening every 3 years when no hypertension is found, seems prudent.

In adults, home BP monitoring is advised and results in better adherence to treatment. 24hr ambulatory BP measurement can identify “non-dippers” who would benefit from intensified regimens and evening dosing. The target BP is ≤140/90 mm Hg, but should be individualized and lowered to ≤30/80 mm Hg in patients with left ventricular dysfunction, intracranial aneurysm, diabetes, or proteinuria. In young patients with ADPKD with chronic kidney disease (CKD) stage 1-2, tight BP control (BP target, 95-110/60-75 mm Hg) may be advantageous. Studies have shown that in recent decades, patients with ADPKD have experienced lower cardiovascular mortality, which could be attributable to improved BP control.

Lifestyle modification and medical treatment can help control BP. It is beneficial to encourage a healthy lifestyle in families with a history of ADPKD through exercise programs, low salt intake (≤2g/d), and maintenance of healthy weight (body mass index, 20-25 kg/m²). Salt restriction should be emphasized, as patients with ADPKD are usually overloaded with sodium and have sodium-sensitive hypertension. ACE inhibitors or
angiotensin receptor blockers (ARBs), which are equally effective for RAAS blockade, should be a first line therapy. Of note, coadministration of these drugs does not confer additional benefit. Caution should be used when prescribing ACE inhibitors or ARBs to women of child-bearing age, given their teratogenic risk. It is not clear which antihyptertensive drug class should be used as second line. Beta-blockers or alpha-blockers are preferred for patients with comorbid conditions, such as angina or benign prostatic hyperplasia. Calcium channel blockers and diuretics can also be used, but cautiously: in ADPKD, such drugs might play a role in worsening kidney disease progression.

**Additional Readings**


**Proteinuria**—Proteinuria (>300 mg/d) is present in almost 25% of adults with ADPKD, but rarely exceeds 1 g/d. Proteinuria has prognostic value, as its presence and degree correlates with severity of the disease (e.g., larger TKV, more rapid loss of GFR, and earlier onset of ESRD). Nephrotic syndrome in ADPKD is rarely reported and usually reflects a superimposed glomerular process. Proteinuria should be monitored in patients with ADPKD. It is uncertain whether reduction of proteinuria with ACE inhibitors or ARBs will slow the progression of the disease.

**Pain**—Abdominal and flank pain is reported in 60% of adults with ADPKD. Acute pain is often associated with kidney cyst hemorrhage, infection, or stones. Pain due to kidney cyst infection is usually diffuse, unilateral, and non-radiating as compared to point tenderness in cyst hemorrhage. Diagnosis and therapies of different causes of acute pain are discussed in sections below.

Pain can also be chronic and in some cases debilitating. Such pain is usually due to cyst enlargement that causes kidney capsule stretching or is musculoskeletal in origin. It is typically a steady discomfort exacerbated by walking or prolonged standing. Patients can frequently localize the pain in an abdominal location with one finger. Mechanical (musculoskeletal) back pain is commonly associated with marked enlargement of the
kidneys and/or liver, and is insidious and progressive. It is important to recognize the pattern of pain and pursue a differential diagnosis with a multidisciplinary approach. Managing chronic pain can be challenging, and strategies used in standard pain clinics should be applied to patients with ADPKD. These strategies include physical interventions such as ice massage or heating pads, use of support garments or the Alexander technique, and physical therapy. Pain medications should include non-opioid analgesics like acetaminophen, tramadol, and clonidine. Nonsteroidal anti-inflammatory drugs should be avoided in elderly patients, and should not be used beyond 5 to 7 days. Opioids should be dose modified for GFR when needed to treat moderate to severe pain. In cases of disabling pain, cyst sclerosis and laparoscopic cyst fenestration can be attempted. Percutaneous cyst aspiration can be a useful diagnostic and therapeutic trial prior to more permanent and invasive procedures. Other alternatives for pain control that have been tried successfully in small series include celiac plexus blockade, radiofrequency ablation, spinal cord stimulation, thoracoscopic sympathectomy, laparoscopic kidney denervation, and percutaneous transluminal catheter-based denervation. Success with transluminal catheter-based denervation has been described in recent case reports and is currently undergoing clinical trials in patients with ADPKD.

**Additional Readings**


**Nephrolithiasis**—Nephrolithiasis occurs in 20% to 35% of ADPKD patients, with two-thirds of cases being symptomatic. Stones are usually composed of uric acid and/or calcium oxalate. CT scans are more sensitive than ultrasound in detecting stones. Dual-energy CT scan can distinguish between the 2 types of stones (Figure 7C-D). Increased frequency of nephrolithiasis is attributed to increased urinary stasis and metabolic factors, which include low urinary pH, low citrate concentration, and decreased ammonia excretion. It often is challenging to distinguish between stones and cyst wall or parenchymal calcifications. Medical treatment for nephrolithiasis prevention is similar to the general population. Potassium citrate is a treatment of choice in most cases. Management of obstructing stones is more difficult in patients with ADPKD. Extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy in patients with early disease and normal kidney function are not contraindicated and have been used successfully without increased complications. Flexible ureterorenoscopy with laser fragmentation also can be considered.

**Additional Readings**

Hematuria—Cyst hemorrhage is common in ADPKD. High-density cysts are frequently seen on imaging and likely represent cyst hemorrhage but can also be indicative of proteinaceous content (Figure 7A-B). Cyst hemorrhage can be associated with fever and is often challenging to differentiate from cyst infection. Gross hematuria may be associated with cyst hemorrhage, infection, passage of kidney stone(s), or kidney/urinary neoplasm. Hemorrhages typically resolve within 2 to 7 days. Tests to exclude neoplasm should be completed if symptoms last longer than 1 week or it is the patient’s first hemorrhagic episode and he/she is over 50 years of age. Rare complications of cyst hemorrhage include extensive subcapsular or retroperitoneal hematomas. Management of gross hematuria is mostly conservative with rest, hydration, and avoidance or temporary discontinuation of medications that facilitate bleeding (eg, warfarin, aspirin, or clopidogrel), if feasible. In severe cases of cyst hemorrhage, temporary discontinuation of RAAS inhibitors may be indicated to prevent acute kidney injury. Blood transfusion should be used with caution to prevent sensitization in potential future kidney recipients. Based on a successful experience in a small cohort of patients, the antifibrinolytic agent tranexamic acid can be considered when conservative therapy fails.

Additional Readings


Urinary Tract Infections—Urinary tract infections (UTIs) can occur in 30% to 50% of patients with ADPKD during their lifetime. Cystitis and urethritis are more common in women, and are typically caused by Gram-negative enteric organisms. Treatment of lower UTIs should be initiated promptly, and is not different from treatment in the general population.

Cyst infection and acute pyelonephritis are the most common causes of upper UTI. Abdominal or flank pain and fever are common symptoms on presentation, and should raise suspicion for cyst infection when concurrent with elevated erythrocyte sedimentation rate...
(ESR) or C-reactive protein (CRP). Urinalysis, urine culture with antimicrobial susceptibility testing, blood culture, and imaging with CT scan or MRI should be part of the initial evaluation. Fludeoxyglucose positron emission tomography (FDG-PET) scan is more sensitive than CT or MRI in cyst infection detection (Figure 8). If imaging reveals features of a complex cyst, aspiration of cyst fluid should be considered if clinically feasible and sent for microbiology studies. If pain or unabated fever persist for more than 72 hours, repeat imaging should be obtained to exclude complications that may require intervention (eg, perinephric abscess or urinary tract obstruction), and aspiration of cyst fluid should be considered for microbiologic studies if not performed initially.

Treatment should include intravenous broad-spectrum antibiotics while the patient has systemic symptoms, with transition to oral antibiotics that have good cyst penetration such as ciprofloxacin or other quinolones. Therapy will be tailored according to microbial susceptibility when available. For cases of isolated acute pyelonephritis, the total duration of antibiotic therapy should be for a minimum of 10-14 days. The duration should be extended to a minimum of 4 weeks and up to 6 weeks in the case of infected cyst using an oral quinolone or sulfamethoxazole/trimethoprim as a reasonable alternative. Perinephric abscess requires prolonged intravenous antibiotic therapy with consideration for drainage. Efficacy of antibiotic treatment and infection eradication is defined by resolution of fever, normalization of CRP level, and documentation of at least 2 negative blood and/or urine cultures. Infected cysts larger than 5 cm may be resistant to antibiotic therapy and require percutaneous or surgical drainage. Nephrectomy is rarely needed but is considered in cases of perinephric abscess or emphysematous pyelonephritis that are resistant to antibiotic therapy.

Additional Readings


Renal Cell Carcinoma—Renal cell carcinoma (RCC) is not frequent in ADPKD (occurs in <1% of cases), nor does it occur more commonly in patients with ADPKD than in those with other kidney diseases. Nevertheless, RCC can arise at an earlier age in patients with ADPKD than it does in the general population and is often bilateral, multicentric, and sarcomatoid in type. Fever and systemic symptoms (anorexia, fatigue, and weight loss) are common presenting symptoms. In the setting of ADPKD, RCC is a rare cause of pain and challenging to diagnose (Figure 7E-F). Potential signs of a carcinoma include rapid growth of a complex cyst; a solid mass detected by ultrasonography; speckled calcifications visible by CT; and contrast enhancement, regional lymphadenopathies, and tumor thrombus on CT or MRI. Screening for RCC in patients with ADPKD is not currently warranted.
**ESRD**—Most patients with ADPKD reach ESRD, although its onset varies between individuals. Almost 50% of patients with ADPKD reach ESRD by age 60, with a mean age of ESRD onset of 58.1 years in patients with *PKD1*-associated disease. Patients with ADPKD represent 9.8% and 5% of prevalent ESRD patients in Europe and the United States, respectively. The lower prevalence in the United States is explained by the dilution effect of higher diabetes prevalence there as compared to Europe. Patients with ADPKD have an overall favorable prognosis as compared to the general ESRD population. Kidney transplantation is the optimal renal replacement therapy (RRT). Preemptive transplantation can be planned given the natural course of the disease, and has been associated with better outcomes. In our opinion, patients with ADPKD preparing for kidney transplantation should be screened for intracranial aneurysms (ICA) by brain magnetic resonance angiogram (MRA). Nephrectomy prior to transplantation for space considerations varies widely between practices, and is performed in 20-25% of patients. Other indications for nephrectomy include recurrent and/or severe infection, bleeding, intractable pain, symptomatic nephrolithiasis, and suspicion for kidney malignancy. Nephrectomy is associated with perioperative morbidity, mortality, and risk of sensitization due to need for blood transfusion. The hand-assisted laparoscopic approach is less invasive. Timing of the nephrectomy can also be concurrent with the transplant surgery or post transplantation. Some post-transplantation complications may be more frequent in ADPKD patients, such as new-onset diabetes mellitus, diverticulitis, and thromboembolic events.

The second option for RRT is either hemodialysis or peritoneal dialysis. ADPKD is not a contraindication for PD therapy, but this modality is less common: patients with ADPKD experience challenges in accommodating large volumes of peritoneal dialysate and have an increased risk of abdominal wall hernias and peritonitis secondary to cyst infection. Patients with ADPKD who receive hemodialysis have higher survival compared to patients without ADPKD undergoing the same treatment. Higher hemoglobin levels also have been noted in patients with ADPKD treated by hemodialysis. Patients with ADPKD who have received RRT do not appear to be at higher risk for developing RCC as compared to patients with other kidney diseases.

**Additional Readings**


**Conventional Strategies for Renoprotection**—Families at risk for ADPKD are advised to implement a healthy lifestyle for all family members. Some interventions could be theoretically beneficial based on the current understanding of the disease pathogenesis, particularly early detection, and strict control of hypertension. Other interventions include drinking water throughout the day to inhibit release of antidiuretic hormone, for a goal urine osmolality of 250 mOsm/Kg; low sodium intake (≤ 2g/d); healthy weight and lifestyle with regular exercise; a low threshold to initiate statins for hyperlipidemia; and avoiding high caffeine intake in order to prevent cAMP accumulation. Lowering daily protein intake to 0.8 g per kilogram of body weight when eGFR is less than 30 ml/min/1.73 m² is recommended and should be done through a renal dietician to monitor for malnutrition. Moderation in alcohol intake is recommended as well. Hard contact sports such as rugby or American football should be avoided, but individual risk assessment is advised. Patients should be assessed for cardiovascular risk factors and treated aggressively. If applicable, patients should be strongly advised and counseled for smoking cessation.

**Novel Strategies for Nephroprotection**—Novel therapies have been proposed and tested based on the improved understanding of ADPKD pathophysiology. However, the role of these novel therapies in treating ADPKD has not yet been established. The TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3:4 trial evaluated the effect of tolvaptan, a vasopressin V2 receptor antagonist, on ADPKD disease progression. Treatment with tolvaptan in ADPKD patients with GFR > 60 ml/min and TKV ≥750 ml showed significant effect on the rate of growth of TKV (~48%) and the rate of eGFR decline (~26%). In Japan (March 2014), Canada (February 2015), and the European Union (May 2015), tolvaptan has been approved to delay progression of ADPKD in patients with rapid increase in TKV. In the United States, Food and Drug Administration approval has been deferred until further data is available on potential benefits and risks.

Sirolimus and everolimus, mTOR-inhibiting rapamycin analogs, failed to show benefit in clinical trials despite encouraging results in animal models of PKD; this was likely due to
the fact that therapeutic levels could not be reached without inducing systemic toxicity. The ALADIN study randomized ADPKD patients to the somatostatin analogue octreotide or placebo, and noted a favorable trend in halting TKV increase. However, statistical significance was not reached in the study, leading the investigators to call for larger trials. DIPAK1 (Developing Interventions to Halt Progression of ADPKD 1) and LIPS (Lanreotide In Polycystic kidney disease Study) are ongoing clinical trials evaluating the effect of the somatostatin analogue lanreotide on disease progression in ADPKD patients with CKD stage 3 or CKD stages 2-3, respectively. Pravastatin, a HMG-CoA reductase inhibitor, has shown promising results on disease progression in a small randomized clinical trial in children with ADPKD. Larger and longer studies in adults are needed to confirm these results.

**Additional Readings**


**Extrarenal Manifestations**

ADPKD is a systemic disease, and is associated with several extrarenal manifestations that have implications on mortality, morbidity, and quality of life. The different extrarenal manifestations in ADPKD are summarized in the second half of Table 4.

**Hepatic cysts**—Liver cysts are the most common extrarenal manifestation of ADPKD. By 30 years old, 80% of patients show evidence of liver cysts on MRI. The burden of liver cysts increases with age and is worse in women. It is estimated that 20% of patients eventually develop symptoms due to polycystic liver disease. Risk factors for severe polycystic liver
Liver cysts can be complicated by infections, rupture, or hemorrhage. Most patients are asymptomatic and managed conservatively, and liver dysfunction is unusual. Liver imaging should be included in the initial evaluation of patients with ADPKD. Women with severe polycystic liver disease should be advised to avoid exogenous hormones or hormone-containing contraceptives.

Medical or surgical interventions should aim to alleviate symptoms and improve quality of life. Options include percutaneous aspiration and sclerotherapy with ethanol or other agents, deroofing of cysts surgically or laparoscopically, and partial liver resection (Figure 9). The latter procedure should be reserved for patients with severe symptomatic polycystic liver disease and liver anatomy that allows preservation of at least two contiguous liver segments with adequate hepatic venous drainage. Patients fitting these criteria should be referred to centers with substantial expertise in this surgery. Partial resection provides significant and sustained symptom relief. As a last resort, liver transplantation is considered for patients who are not candidates for partial liver resection. Patients with polycystic liver disease typically have low priority on the transplant waiting list due to their low MELD (Model for End-Stage Liver Disease) score (international normalized ratio and albumin are usually normal). The somatostatin analogues octreotide and lanreotide have been tested in clinical trials and have been shown to be associated with a significant reduction in liver cyst volume. Benefit is mostly seen during the first year of their use, and the treatment effect is greater in women under age 48. Currently, somatostatin analogues are not approved for use to slow polycystic liver disease progression and should be reserved for use in research studies. Such drugs have been prescribed in rare cases for compassionate use in patients with very severe polycystic liver disease without other options.

Liver cyst infections are a common complication of polycystic liver disease. Fever, right upper quadrant tenderness, and elevated inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) should raise clinical suspicion. MRI and CT scan findings are not specific for infected cyst identification. FDG-PET is more sensitive. Treatment of liver cyst infections entails a prolonged course of parenteral broad-spectrum antibiotics, followed by oral antibiotics. Therapy should be guided by culture, antimicrobial susceptibility, and good cyst penetration capability (such as possessed by quinolones).

**Additional Readings**


Intracranial Aneurysms—ICA occur more frequently in patients with ADPKD than in the general population: asymptomatic ICA is detected by MRA in 9-12% and 2-3% of ADPKD patients and the general population, respectively. Family history of ICA is an important risk factor for the condition; if family history is positive, prevalence increases from 6% to 20-27%. ICA can occur in both PKD1- and PKD2-associated disease. ICA rupture is associated with a mortality rate of up to 50%. In patients with ADPKD, the average age at ICA rupture is 40 years, younger than that in the general population. Rupture usually presents as sudden onset of a severe headache described as thunder clap headache. Increased size, posterior location, family history of ICA, and personal history of subarachnoid hemorrhage are potential risks for rupture. The location of ICA in ADPKD is typically the anterior circle of Willis (80-90% of cases). The large majority of aneurysms that are detected by presymptomatic screening are found to be less than 7 mm in size. Indication, timing, and frequency of screening are not well defined. Screening for asymptomatic ICA is reasonable for patients with ADPKD who also have a family history of ICA or a personal history of intracranial hemorrhage. Individuals in high-risk professions (eg, pilots) should be screened as well. Routine and long-standing headaches are not an indication for screening. MRA without gadolinium or CT angiography can be used for screening, but MRA is preferable to avoid exposure to iodinated contrast agent. Patients with positive family history and negative results on screening should undergo rescreening in 5-10 years.

Conservative management is advised for ADPKD patients with small (<7mm), anterior circulation asymptomatic ICA detected by presymptomatic screening (Figure 10). Management of unruptured ICA larger than 7 mm or in the posterior circulation should involve a multidisciplinary team of neurologists, neurosurgeons, and interventional neuroradiologists. Endovascular approach with coil embolization is more favorable than surgical procedures. Risk of growth and rupture of small asymptomatic ICA is generally low. Serial imaging is reasonable, starting at 6-month intervals. Later, screens should be performed yearly and then every 2-3 years once stability is established. Modifiable risk factors of ICA growth have been identified in the general population and should be addressed in patients with ADPKD. These factors include smoking cessation, BP control, limited alcohol intake, and control of cardiovascular risk factors.

Additional Readings

Additional Extrarenal Manifestations—Other organs are involved in ADPKD. Most manifestations are asymptomatic and screening is not recommended. Mitral valve prolapse occurs in 25% of patients. Pericardial effusions also are common (prevalence of 35%), but are typically small with no hemodynamic significance. Idiopathic dilated cardiomyopathy and left ventricular non-compaction have been rarely associated with ADPKD. Screening echocardiography is only recommended if a murmur or cardiovascular symptoms are noted. Patients with ADPKD may be predisposed to a vascular phenotype. Cases of aneurysms of large arteries, such as the ascending aorta, popliteal, coronary, and splenic arteries have been reported. Arachnoid membrane cysts occur in 8-12% of patients, and are typically asymptomatic but may slightly increase the risk of subdural hematoma. Spinal meningeal cysts are found in 1.7% of patients with ADPKD and may rarely cause intracranial hypotension that presents with orthostatic headache. Pancreatic cysts are observed in 10% of cases and are almost always asymptomatic. Diverticulosis occurrence is increased in patients with ADPKD who have reached ESRD. Abdominal wall hernias have been noted more frequently in patients with ADPKD as compared to ESRD patients without ADPKD. Seminal vesicle cysts are found in 40% of men with ADPKD without correlation to semen abnormalities. Some studies have linked ADPKD with reproductive issues (infertility and sperm abnormalities) in men but not in women. Bronchiectasis may occur in up to 37% patients with ADPKD, but typically is mild. Congenital hepatic fibrosis complicated by portal hypertension is rare in ADPKD, relative to autosomal recessive polycystic kidney disease. Clinical suspicion should be raised if patients have increased liver echogenicity on ultrasound, enlarged left lobe of liver, thrombocytopenia, or splenomegaly.

Additional Readings


COUNSELING, PREGNANCY, AND REPRODUCTIVE ISSUES

Family planning should be discussed with patients, and options reviewed. Both parents should be counseled about the risk of passing the disease to their offspring, as well as the risk to the fetus and the mother during pregnancy. Women of reproductive age with ADPKD, particularly those with severe polycystic liver disease, should be advised about the potential worsening of their liver disease when exposed to estrogen or progesterone. Multiple
pregnancies (>3) have been associated with a greater rate of GFR decline in ADPKD. Preimplantation genetic diagnosis has been used in ADPKD to select and implant healthy embryos created by in vitro fertilization. If available, this option should be part of the reproductive choices and counseling.

Antihypertensive treatment should be reviewed and adjusted for safety during pregnancy. RAAS inhibitors should be discontinued preemptively. Women with ADPKD and normal BP and kidney function have a favorable course during pregnancy, but are at slightly higher risk of developing pregnancy-induced hypertension and preeclampsia. Similar to women with CKD, pregnant women with ADPKD and reduced kidney function are at higher risk for early fetal loss, accelerated loss of kidney function, and difficulty in controlling blood pressure. Referral to an obstetrician with expertise in treating women with high-risk pregnancies is recommended.

Additional Readings


ACKNOWLEDGEMENTS

*Support:* Supported by NIDDK grant DK044863 and by the Mayo Clinic Translational PKD Center (DK090728).
The image shows a genetic map of the PKD1 and PKD2 genes. The PKD1 gene is depicted with 15 exons, numbered 1 to 15, with exons 2 and 4 being larger than the others. The PKD2 gene is shown with 15 exons, numbered 1 to 15, with exons 2 to 7 being larger than the others. The genes are represented as linear structures with exons marked by vertical lines. The PKD1 transcript spans 1 kb, and the PKD2 transcript spans 1 kb. The diagram also includes a scale indicating distances of 3 kb and 1 kb.
Figure 1.
A) *PKD1* and *PKD2* genes and transcripts. Numbered boxes indicate exons; in total there are 46 for *PKD1* (top) and 15 for *PKD2* (bottom). The coding regions are shaded; 5' and 3' untranslated regions are not shaded. Reproduced from Torres et al (“Autosomal dominant polycystic kidney disease.” Lancet. 2007;369(9569):1287-301) with permission of Elsevier.

B) Predicted structures of polycystin 1 (PC1) and polycystin 2 (PC2): PC1 is a receptor-like protein with a large ectodomain, 11 transmembrane domains, and a cytoplasmic tail consisting of ~200 amino acids. The last six transmembrane domains of PC1 are homologous to the transmembrane region of PC2. PC2 is a transient receptor potential–like calcium channel that has an EF-hand motif and an endoplasmic reticulum retention signal in the carboxy (C) terminus and a proposed cilia targeting sequence in the amino (N) terminus.
PC1 and PC2 physically interact through coiled-coil domains in the cytoplasmic tail of PC1 and in the carboxy-terminal tail of PC2. Reproduced from Chebib et al ("Vasopressin and disruption of calcium signaling in polycystic kidney disease." [published online ahead of print April 14, 2015] Nat Rev Nephrol. doi: 10.1038/nrneph.2015.39) with permission of Nature Publishing Group. Abbreviations: GPCR, G protein–coupled receptor; ER, endoplasmic reticulum; LLR, leucine rich repeat;
Figure 2.
Putative up- or down-regulated pathways in polycystic kidney disease. Dysregulation of intracellular Ca\(^{2+}\) and increased concentrations of cAMP play a central role. Increased accumulation of cAMP in polycystic kidneys may be explained by the following hypotheses. (1) Reduced Ca\(^{2+}\) activates Ca\(^{2+}\)-inhibitable AC6, inhibits Ca\(^{2+}\)/calmodulin-dependent PDE1 directly, and cGMP-inhibitable PDE3 indirectly. (2) Disruption of a ciliary protein complex (comprising AKAP150, AC5/6, PC2, PDE4C, and PKA), which normally restraints cAMP signaling through inhibition of AC5/6 activity by PC2–mediated Ca\(^{2+}\) entry and degradation of cAMP by PDE4C transcriptionally controlled by HNF1β. (3) Depletion of the ER Ca\(^{2+}\) stores that triggers oligomerization and translocation of STIM1 to the plasma membrane, where it recruits and activates AC6. (4) Other contributory factors include disruption of PC1 binding to heterotrimeric G proteins, upregulation of the V2R, and increased levels of circulating vasopressin or accumulation of forskolin, lisophosphatidic acid, ATP, or other AC agonists in the cyst fluid. Increased cAMP levels disrupt tubulogenesis, stimulate chloride and fluid secretion, and activate prolifervative signaling pathways, including MAPK/ERK (in a Src- and Ras-dependent manner), mTOR, and β-catenin signaling. Activated mTOR transcriptionally stimulates aerobic glycolysis, increasing ATP synthesis and lowering AMP levels, which together with B-Raf–dependent activation of LKB1, inhibits AMPK, further enhancing mTOR activity and CFTR-driven chloride and fluid secretion. PKA signaling also activates a number of transcription factors,

*Am J Kidney Dis. Author manuscript; available in PMC 2017 May 01.*
including STAT3. Activated STAT3 induces the transcription of cytokines, chemokines, and growth factors that, in turn, activate STAT3 signaling in interstitial alternatively activated M2 macrophages and result in a feedforward loop between cyst-lining cells and M2 macrophages. Aberrant integrin–extracellular membrane interaction and cAMP signaling within focal adhesion complexes may contribute to the increased adhesion of cyst-derived cells to laminin-322 and collagen. Abbreviations: AKAP, A-kinase anchoring protein; AC, adenyl cyclase; AMPK, AMP kinase; AMP, adenosine monophosphate; ATP, adenosine triphosphate; B-Raf, B rapidly accelerated fibrosarcoma kinase; cAMP, cyclic AMP; cGMP, cyclic guanosine monophosphate; ER, endoplasmic reticulum; ERK, extracellularly-regulated kinase; LKB1, liver kinase B1; MAPK, mitogen-activated protein kinase; PC, polycystin; PDE, phosphodiesterase; PKA, protein kinase A; STAT3, signal transducer and activator of transcription 3; STIM1, stromal interaction molecule 1; V2R, vassopressin 2 receptor; HNF1β, hepatocyte nuclear factor 1β; mTOR, mechanistic target of rapamycin; CFTR, cystic fibrosis transmembrane conductance regulator. Reproduced from Torres and Harris “Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease.” J Am Soc Nephrol. 2014 Jan;25(1):18-32 with permission of American Society of Nephrology.
Figure 3.
Right (R; 1,830 g) and left (L; 1,040 g) nephrectomy specimens resected from a 51 year-old woman with autosomal polycystic kidney disease four months after kidney transplantation.
Figure 4.
A) Axial contrast enhanced computed tomography (CT) image and B) coronal T2-weighted single shot fast spin echo magnetic resonance imaging (MRI) in a 39 year old woman with autosomal polycystic kidney disease. Contrast administration is necessary to differentiate the cystic tissue from preserved parenchyma and to detect small cysts using CT, but it is not necessary using MRI.
Figure 5.
Practical algorithm for diagnostic evaluation of patients 18 years or older with kidney cysts.

* At least one affected member with ESRD ≤ 50 years old strongly suggests PKD1 mutation; at least one affected family member without ESRD ≥ 70 years old suggests PKD2 mutation.

† Polycystic kidneys with multiple angiomyolipomas (contiguous PKD1-TSC2 syndrome)
ADTKD-MUC1, Autosomal dominant tubulointerstitial kidney disease – tumor-associated mucin (previously known as medullary cystic kidney disease type 1); ADTKD-UMOD, Autosomal dominant tubulointerstitial kidney disease – Uromodulin (previously known as medullary cystic kidney disease type 2); ADPKD, autosomal polycystic kidney disease; PKD1, polycystic kidney disease 1; PKD2, polycystic kidney disease 2; US, ultrasound; MRI, magnetic resonance imaging; ADPLD, autosomal dominant polycystic liver disease; ARPKD, autosomal recessive polycystic kidney disease; RCC, renal cell carcinoma; CKD, chronic kidney disease; OFD1, oral-facial-digital syndrome type 1; ESRD, end-stage renal disease.
Figure 6.
An imaging classification of autosomal polycystic kidney disease predicts the change in estimated glomerular filtration rate (eGFR) over time in patients with typical, bilateral, and diffuse distribution of cysts. (A) The A through E classification is based on height-adjusted total kidney volume (htTKV) and age at the time of imaging, assuming kidney growth rates of <1.5%, 1.5%–3%, 3%–4.5%, 4.5%–6%, or >6% per year and a theoretic, initial htTKV of 150 ml/m; the dots correspond to the patients in panel B. (B) Magnetic resonance imaging studies corresponding to three 41 year-old patients in classes A (bottom), C (middle) and E (top), respectively. (C) Estimated glomerular filtration rate (eGFR) slopes in a cohort of 376 patients stratified by imaging class (−0.23, −1.33, −2.63, −3.48, and −4.78 ml/min/1.73 m² per year for classes A through E, respectively); the average eGFR at baseline (75 ml/min/1.73 m²) and the average age at baseline (44 years) for all patients were used for the model; values for normal slope were obtained from a population of healthy kidney donors; eGFR slopes were significantly different among the classes, and all but class A were significantly different from the control population of healthy kidney donors. Panels A and B courtesy of MV Irazabal; panel C reproduced from Irazabal MV et al (“Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.” J Am Soc Nephrol. 2015;26(1):160-72) with permission of American Society of Nephrology.
Figure 7.
Axial unenhanced computed tomography (CT) scans showing (A, B) hyperdense lesions in the left kidney due to cyst and parenchymal hemorrhage and (C) a small staghorn calculus in a right polycystic kidney (D) containing uric acid on a dual-energy CT. (E) Coronal T1-weighted and (F) axial T2-weighted images showing an irregular mass (red arrows) in the lower pole of a left polycystic kidney proven to be a renal cell carcinoma.
Figure 8.
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography scan in a 45-year-old woman with a one-month history of malaise and low grade fever. The scan shows a 6-7 cm cyst within the most inferior aspect of the right polycystic kidney with (A, B) an intense focus of hypermetabolism along its anterior margin and (A, C) more moderate hypermetabolism about the periphery of the remainder of the cyst. Other activity seen within both kidneys represents activity within remnant functioning renal parenchyma and excreted activity within the collecting systems.
Figure 9.
(A) Deep-seated large cyst in the right hepatic lobe best treated by cyst aspiration and alcohol sclerosis. (B) Superficial large cyst arising from the right lobe of the liver suited for laparoscopic fenestration. (C) Polycystic liver disease involving both lobes, more severely segments VII and VIII; this patient is not a good candidate for combined liver resection and cyst fenestration because of the distribution of the cysts and involvement of the less severely affected segments by many small cysts with further potential for growth. This patient might benefit from embolization of hepatic artery branches supplying segments VII and VIII that have no recognizable hepatic parenchyma. (D and E) Polycystic liver (D) before and (E) after combined right lobectomy and cyst fenestration (note compensatory hypertrophy of the left lobe after surgery). (F) Massive polycystic liver without relative preservation of any liver segment; the only feasible treatment in this patient is liver transplantation. Reproduced from Torres (“Treatment of polycystic liver disease: one size does not fit all.” Am J Kidney Dis. 2007;49(6):725-8) with permission of Elsevier.
Figure 10.
MR follow-up illustrating the stability of small intracranial aneurysms detected by pre-symptomatic screening in ADPKD patients. (A) A 59-year-old woman was found to have a 4.0-mm right carotid siphon aneurysm in 1991 that remained unchanged during 17 years of follow-up. (B) A 45-year-old woman was found to have a 2.0-mm basilar tip aneurysm that remained unchanged between 1991 and 2008. (C) A 49-year-old woman was found to have a 6.0-mm right carotid siphon aneurysm in 1992 that also remained unchanged over 17 years of follow-up. Reproduced from Irazabal et al (“Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.” Clin J Am Soc Nephrol. 20116(6):1274-85) with permission of American Society of Nephrology.
Table 1

*PKD1*- and *PKD2*-associated ADPKD

<table>
<thead>
<tr>
<th></th>
<th><em>PKD1</em>-associated ADPKD</th>
<th><em>PKD2</em>-associated ADPKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene location</td>
<td>16p13.3</td>
<td>4q21</td>
</tr>
<tr>
<td>Protein product</td>
<td>Polycystin 1</td>
<td>Polycystin 2</td>
</tr>
<tr>
<td>Year gene Discovered</td>
<td>1994</td>
<td>1996</td>
</tr>
<tr>
<td>No. of known pathogenic mutations in gene</td>
<td>&gt;1270</td>
<td>&gt;200</td>
</tr>
<tr>
<td>Function of protein product</td>
<td>Receptor, adhesion molecule (not well understood)</td>
<td>Calcium-permeable nonselective cation channel</td>
</tr>
<tr>
<td>Proportion of ADPKD cases</td>
<td>64-85%</td>
<td>15-36%</td>
</tr>
<tr>
<td>No. of cysts</td>
<td>More numerous</td>
<td>Less numerous</td>
</tr>
<tr>
<td>Mean age at ESRD incidence (y)</td>
<td>58.1</td>
<td>79.7</td>
</tr>
</tbody>
</table>

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ESRD, end-stage renal disease.
Table 2

Performance of ultrasound-based unified criteria for diagnosis or exclusion of ADPKD in patients with a positive family history

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Imaging Findings</th>
<th>PKD1</th>
<th>PKD2</th>
<th>Unknown gene type</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PPV=100% Sensitivity=94.3%</td>
<td>PPV=100% Sensitivity=69.5%</td>
<td>PPV=100% Sensitivity=81.7%</td>
</tr>
<tr>
<td>15-30</td>
<td>A total of ≥ 3 cysts *</td>
<td>PPV=100% Sensitivity=96.6%</td>
<td>PPV=100% Sensitivity=94.9%</td>
<td>PPV=100% Sensitivity=95.5%</td>
</tr>
<tr>
<td>30-39</td>
<td>A total of ≥ 3 cysts *</td>
<td>PPV=100% Sensitivity=92.6%</td>
<td>PPV=100% Sensitivity=88.8%</td>
<td>PPV=100% Sensitivity=90.9%</td>
</tr>
<tr>
<td>40-59</td>
<td>≥ 2 cysts in each kidney</td>
<td>PPV=100% Sensitivity=92.6%</td>
<td>PPV=100% Sensitivity=88.8%</td>
<td>PPV=100% Sensitivity=90.9%</td>
</tr>
</tbody>
</table>

For Diagnostic Exclusion

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Imaging Findings</th>
<th>PKD1</th>
<th>PKD2</th>
<th>Unknown gene type</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-30</td>
<td>No kidney cyst</td>
<td>NPV=99.1% Specificity=97.6%</td>
<td>NPV=93.5% Specificity=96.6%</td>
<td>NPV=90.8% Specificity=97.1%</td>
</tr>
<tr>
<td>30-39</td>
<td>No kidney cyst</td>
<td>NPV=100% Specificity=96.0%</td>
<td>NPV=96.8% Specificity=93.8%</td>
<td>NPV=98.3% Specificity=94.8%</td>
</tr>
<tr>
<td>40-59</td>
<td>No kidney cyst</td>
<td>NPV=100% Specificity=93.9%</td>
<td>NPV=100% Specificity=93.7%</td>
<td>NPV=100% Specificity=93.9%</td>
</tr>
</tbody>
</table>


Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; NPV, negative predictive value; PPV, positive predictive value.

*Unilateral or bilateral.
### Table 3

Differential diagnosis of other kidney cystic diseases

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Inheritance</th>
<th>Family History</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple benign simple cysts</td>
<td>Acquired</td>
<td>none</td>
<td>Relatively common in the general population; increase in number and size with age (ages 30-60, uncommon, rarely multiple or bilateral; age 60-99, uncommon to have ≥4 cysts in each kidney); kidney ultrasound in family members may be helpful</td>
</tr>
<tr>
<td>Acquired kidney cystic disease</td>
<td>Acquired</td>
<td>none</td>
<td>Seen in advanced CKD, particularly in patients receiving RRT; Cysts are small, bilateral and multiple (&gt;4 cysts in each kidney); Kidneys are small to normal in size.</td>
</tr>
<tr>
<td>Localized kidney cystic disease</td>
<td>Acquired</td>
<td>None</td>
<td>Uncommon, benign, unilateral, not progressive</td>
</tr>
<tr>
<td>Autosomal recessive polycystic kidney disease (ARPKD)</td>
<td>Autosomal recessive</td>
<td>25% concordance between siblings</td>
<td>Affects ~1 in 20,000; in neonates, death in 30%; enlarged echogenic kidneys and pulmonary hypoplasia; in older children, biliary dysgenesis (congenital hepatic fibrosis, intrahepatic bile duct dilatation) resulting in portal hypertension and cholangitis; collecting duct ectasia and macrocystic changes associated with calcifications, hyperension, and/or decrease in kidney function</td>
</tr>
<tr>
<td>Tuberous sclerosis complex (TSC)</td>
<td>Autosomal dominant</td>
<td>Absent in 2/3 of cases</td>
<td>Affects ~1 in 10,000 live births; skin lesions (facial angiofibromas, periungual fibroma, hypomelanotic macules, shagreen patch); &gt;90% have cerebral pathology (cortical tuber, subependymal nodules, giant cell astrocytoma); 90% have kidney manifestations (polycystic kidneys, angiomylipomas); 50-70% have retinal hamartomas; 50% have pulmonary lymphangioleiomyomatosis</td>
</tr>
<tr>
<td>PKD1-TSC contiguous gene syndrome</td>
<td>Autosomal dominant</td>
<td>Spontaneous presentation frequent</td>
<td>Presentation with polycystic kidneys at an early age, with kidney angiomyolipomas frequently presenting after the first year of life</td>
</tr>
<tr>
<td>von Hippel-Lindau syndrome</td>
<td>Autosomal dominant</td>
<td>~ 20% de novo</td>
<td>Affects ~1 in 36,000; Cerebellar and spinal hemangioblastoma; retinal angiomas; serous cystadenomas and neuroendocrine tumors of pancreas; pheochromocytoma; renal cell carcinoma</td>
</tr>
<tr>
<td>Medullary sponge kidney (MSK)</td>
<td>Unclear; autosomal dominant in some cases</td>
<td>Familial clustering reported</td>
<td>Affects ~1 in 5000; tubular dilatation of the collecting ducts giving the appearance of &quot;brush&quot; or linear striations on intravenous pyelogram; medullary nephrocalcinosis; kidney stones; kidney cortex spared on CT scans or MRI</td>
</tr>
<tr>
<td>Medullary cystic kidney disease (MCKD)**</td>
<td>Autosomal dominant</td>
<td>rare</td>
<td>Slowly progressive kidney disease; medullary cysts (but uncommon in families with type 2 MCKD**); hyperuricemia and gout (in type 2 MCKD**); small to normal sized kidneys.</td>
</tr>
<tr>
<td>Renal cysts and diabetes syndrome (RCAD/MODY5/HNF-1B*)</td>
<td>Autosomal dominant</td>
<td>Spontaneous mutations (often deletions) in 50%</td>
<td>Kidney cysts or malformation in 90%, diabetes mellitus in 45%, hypomagnesemia in 40%, genital tract abnormalities in 20%, hyperuricemia in 20%, elevated liver enzymes in 15%</td>
</tr>
<tr>
<td>Bilateral parapelvic cysts</td>
<td>Unknown</td>
<td>Lympathic (not epithelial) cysts; distort the kidney pelvis, infundibula, and calyces.</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ADTKD, autosomal dominant tubulointerstitial kidney disease; ESRD, end-stage renal failure; MODY5, maturity onset diabetes mellitus of the young type 5; PKD1, polycystic kidney disease 1; CKD, chronic kidney disease; RRT, renal replacement therapy; CT, computed tomography; MRI, magnetic resonance imaging; MUC1, tumor-associated mucin; UMOD, uromodulin; HNF-IB, hepatocyte nuclear factor 1β;

*Current designation is ADTKD-HNF1B

**Use of the term MCKD is discouraged; what was formerly type 1 MCKD should be referred as ADTKD-MUC1 and what was formerly type 2 MCKD should be referred as ADTKD-UMOD.
## Table 4

### Kidney and extrarenal manifestations in ADPKD patients

<table>
<thead>
<tr>
<th>PKD manifestation</th>
<th>Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kidney</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary concentration defect</td>
<td>In up to 60% of children</td>
<td>Earliest manifestation</td>
</tr>
<tr>
<td>Hypertension</td>
<td>In 50-70% prior to GFR decline; Average age of onset, 30</td>
<td>Screen children with family history of ADPKD from age 5, then at 3-y intervals if negative</td>
</tr>
<tr>
<td>ESRD</td>
<td>Occurs in 50% by age 60</td>
<td>Mean age of onset, 58 y</td>
</tr>
<tr>
<td>Proteinuria (&gt; 300 mg/d)</td>
<td>Associated with GFR decline</td>
<td>Prognostic marker</td>
</tr>
<tr>
<td>Abdominal/Flank Pain</td>
<td>In 60% of adults</td>
<td>Acute, chronic; multiple causes</td>
</tr>
<tr>
<td>Nephrolithiasis</td>
<td>In 20-35% of patients</td>
<td>Uric acid, Calcium oxalate composition</td>
</tr>
<tr>
<td>Cyst hemorrhage/gross hematuria</td>
<td>In up to 60% of patients</td>
<td>Most resolve within 2-7 d</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>In 30-50% of patients</td>
<td>More common in women</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>In &lt;1% of patients</td>
<td>Risk not increased, may present with systemic symptoms</td>
</tr>
<tr>
<td><strong>Extrarenal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycystic liver disease</td>
<td>In &gt;80% by age 30</td>
<td>Include liver imaging in initial visit</td>
</tr>
<tr>
<td>Intracranial aneurysm</td>
<td>In 20-27% of those with positive family history of intracranial aneurysm; in 9% of those without such family history</td>
<td>Screen if family history of intracranial aneurysm, personal history of intracranial hemorrhage, individuals with high-risk professions, pre-transplantation</td>
</tr>
<tr>
<td>Arachnoid cysts</td>
<td>In 8-12%</td>
<td>Possible increased risk of spontaneous subdural hematoma</td>
</tr>
<tr>
<td>Mitral valve prolapse</td>
<td>In 25%</td>
<td>Screen if symptoms</td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td>In up to 35%</td>
<td>Screen if symptoms</td>
</tr>
<tr>
<td>Pancreatic cysts</td>
<td>In 10%</td>
<td>No screening needed</td>
</tr>
<tr>
<td>Diverticulosis</td>
<td>In 20-25% of those with ESRD</td>
<td>No screening needed</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>In up to 37%</td>
<td>Mild, no screening needed</td>
</tr>
<tr>
<td>Congenital hepatic fibrosis</td>
<td>rare</td>
<td>No screening needed</td>
</tr>
<tr>
<td>Seminal vesicle cysts</td>
<td>In up to 40% male patients</td>
<td>No correlation to semen abnormalities</td>
</tr>
<tr>
<td>Male infertility</td>
<td>associated with ADPKD</td>
<td>Abnormal semen parameters reported</td>
</tr>
</tbody>
</table>

GFR, glomerular filtration rate; ADPKD, autosomal dominant polycystic kidney disease; ESRD, end-stage renal disease